| Primary |
| Hyperuricaemia |
30.3% |
| Hypertension |
21.0% |
| Colitis Ulcerative |
4.2% |
| Gastric Ulcer |
4.2% |
| Renal Failure Chronic |
4.2% |
| Cardiac Failure |
3.4% |
| Constipation |
3.4% |
| Dyslipidaemia |
3.4% |
| Gout |
3.4% |
| Insomnia |
3.4% |
| Schizophrenia |
3.4% |
| Benign Prostatic Hyperplasia |
2.5% |
| Anaemia |
1.7% |
| Angina Pectoris |
1.7% |
| Gastrooesophageal Reflux Disease |
1.7% |
| Hepatitis C |
1.7% |
| Hyperlipidaemia |
1.7% |
| Infection Prophylaxis |
1.7% |
| Microscopic Polyangiitis |
1.7% |
| Osteoarthritis |
1.7% |
|
| Pancytopenia |
10.7% |
| Rash |
10.7% |
| Polymyalgia Rheumatica |
7.1% |
| Pyrexia |
7.1% |
| Renal Failure |
7.1% |
| Shock |
7.1% |
| Cerebral Haemorrhage |
3.6% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
3.6% |
| Eyelid Oedema |
3.6% |
| Gallbladder Cancer Recurrent |
3.6% |
| Granulocytopenia |
3.6% |
| High Density Lipoprotein Increased |
3.6% |
| Interstitial Lung Disease |
3.6% |
| Nausea |
3.6% |
| Palpitations |
3.6% |
| Platelet Count Decreased |
3.6% |
| Pneumonia |
3.6% |
| Post Procedural Haemorrhage |
3.6% |
| Potentiating Drug Interaction |
3.6% |
| Pulmonary Haemorrhage |
3.6% |
|
| Secondary |
| Chronic Hepatitis C |
21.9% |
| Hypertension |
16.7% |
| Prophylaxis |
9.4% |
| Hyperuricaemia |
8.3% |
| Adverse Event |
6.8% |
| Insomnia |
5.2% |
| Arrhythmia |
4.7% |
| Castleman's Disease |
3.6% |
| Dyslipidaemia |
3.6% |
| Cardiac Failure |
3.1% |
| Gastric Ulcer |
2.6% |
| Hepatitis C |
2.1% |
| Iga Nephropathy |
2.1% |
| Anaemia |
1.6% |
| Angina Pectoris |
1.6% |
| Gout |
1.6% |
| Infection Prophylaxis |
1.6% |
| Osteoporosis Prophylaxis |
1.6% |
| Adverse Reaction |
1.0% |
| Benign Prostatic Hyperplasia |
1.0% |
|
| Pyrexia |
18.2% |
| Platelet Count Decreased |
9.1% |
| Rhabdomyolysis |
9.1% |
| Agranulocytosis |
6.1% |
| Pneumonia |
6.1% |
| Rash |
6.1% |
| Retinal Haemorrhage |
6.1% |
| Blood Creatine Phosphokinase Increased |
3.0% |
| Blood Pressure Decreased |
3.0% |
| Eosinophil Count Increased |
3.0% |
| Gamma-glutamyltransferase Increased |
3.0% |
| Hepatitis Acute |
3.0% |
| High Density Lipoprotein Increased |
3.0% |
| Hyperuricaemia |
3.0% |
| Interstitial Lung Disease |
3.0% |
| Medication Error |
3.0% |
| Pulmonary Haemorrhage |
3.0% |
| Renal Failure Acute |
3.0% |
| Respiratory Failure |
3.0% |
| Retinitis |
3.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
24.5% |
| Chronic Hepatitis C |
21.4% |
| Hepatitis C |
10.6% |
| Prophylaxis |
9.0% |
| Hypertension |
7.9% |
| Hyperuricaemia |
5.8% |
| Cardiac Failure |
3.0% |
| Drug Use For Unknown Indication |
2.8% |
| Nephrogenic Anaemia |
2.8% |
| Rheumatoid Arthritis |
1.6% |
| Diabetes Mellitus |
1.4% |
| Mantle Cell Lymphoma |
1.3% |
| Constipation |
1.2% |
| Insomnia |
1.1% |
| Cardiac Failure Chronic |
1.0% |
| Glomerulonephritis Chronic |
1.0% |
| Diabetic Nephropathy |
1.0% |
| Renal Failure Chronic |
1.0% |
| Gastrooesophageal Reflux Disease |
0.9% |
| Rash |
0.9% |
|
| Renal Impairment |
24.3% |
| White Blood Cell Count Decreased |
9.6% |
| Rash |
7.4% |
| Neutrophil Count Decreased |
6.1% |
| Decreased Appetite |
5.7% |
| Drug Eruption |
5.2% |
| Anaemia |
4.3% |
| Retinopathy |
3.5% |
| Tumour Lysis Syndrome |
3.5% |
| Bronchitis |
3.0% |
| Oedema Peripheral |
3.0% |
| Pyrexia |
3.0% |
| Sepsis |
3.0% |
| Erythema |
2.6% |
| Haemoglobin Decreased |
2.6% |
| Interstitial Lung Disease |
2.6% |
| Malaise |
2.6% |
| Platelet Count Decreased |
2.6% |
| Renal Disorder |
2.6% |
| Thirst |
2.6% |
|
| Interacting |
| Gastrooesophageal Reflux Disease |
100.0% |
|
| Potentiating Drug Interaction |
100.0% |
|
